Hi vwboy, there would be quite a number of new investors to RAP...

Hi vwboy, there would be quite a number of new investors to RAP that would have missed this announcement . So sorry to the old hands for reposting !

ResApp Begins Field Evaluation with Leading Global Humanitarian Organisation
Perth, Western Australia, 15 September 2016 -- ResApp Health Limited (ASX: RAP), in partnership with UniQuest (the main commercialisation company of The University of Queensland), is pleased to announce that it has shipped smartphones to a leading global humanitarian organisation under the terms of a non-binding memorandum of understanding to field-test ResApp’s smartphone-based respiratory disease diagnostic tool in the developing world.
According to the World Health Organisation, pneumonia kills more than 950,000 children under five every year, the vast majority in South Asia and sub-Saharan Africa. Many of these deaths are caused by delays in diagnosis due to the lack of high-quality medical care in these regions.
The smartphones include ResApp’s propriety respiratory diagnostic software to enable medical professionals to test the usability of the company’s technology in the field. The field evaluation is a precursor to a large-scale multi-country study of the system’s ability to accurately diagnose respiratory disease.
Tony Keating, CEO and Managing Director of ResApp said, “I am excited to be working with this prestigious humanitarian organisation to not only perform a field trial that will generate additional clinical evidence, but also to garner an in-depth understanding of the local conditions so that we can optimise a product for essential medical personnel working in very challenging environments. We look forward to collaborating closely with this leading humanitarian organisation as we make solid progress in delivering a tool that could significantly reduce the burden of pneumonia in the developing world.”
- ENDS - Contacts
Dr Tony Keating
CEO and Managing Director +61 430 180 659 [email protected]
Mr Brian Leedman
Executive Director and Vice President, Corporate Affairs
+61 412 281 780 [email protected]
ResApp Health Limited ABN 51 094 468 318
Level 24, 44 St Georges Tce, Perth WA 6000
T +61 8 6211 5099 E [email protected] W www.resapphealth.com.au